FREE WHITEPAPER
Avoiding the Pitfalls: Five Lessons for Cell Therapy Manufacturing Success
Practical guidance for sustainable and scalable commercialization — from clinical development to commercial supply.
70%+
Of FDA Complete Response Letters are linked to quality or manufacturing deficiencies
1,800+
Active cell therapy trials are currently underway worldwide
US$70B+
Projected global cell and gene therapy market by 2030
Most CGT programs don’t fail on the science. They fail on manufacturing readiness, partner selection, and supply chain complexity.
Download this free whitepaper to get a practical framework for CMC strategy, partner selection, and commercial readiness — authored by Joe Garrity, Executive Director, Portfolio Management, Specialized Modalities at Lonza.
Download you copy today
"It is never too soon to think commercially. The earlier scalability enters the discussion, the smoother the launch."
Joe Garrity · Executive Director, Portfolio Management, Specialized Modalities, Lonza
Get the Free White Paper
Get practical frameworks for CMC strategy, partner selection, logistics, and commercial readiness.